Search

Exelixis Inc

Chiusa

SettoreSettore sanitario

53.99 0.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

53.48

Massimo

54.66

Metriche Chiave

By Trading Economics

Entrata

1.6M

212M

Vendite

18M

629M

P/E

Media del settore

16.453

57.371

EPS

0.82

Margine di Profitto

33.729

Dipendenti

1,077

EBITDA

-12M

263M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-3.99% downside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-876M

13B

Apertura precedente

53.39

Chiusura precedente

53.99

Notizie sul Sentiment di mercato

By Acuity

50%

50%

171 / 340 Classifica in Healthcare

Exelixis Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 20:06 UTC

Exelixis Inc shares are higher today, continuing a trend since Thursday's close. Broader biotechnology sector gains may be contributing to the movement.

20 ago 2026, 23:36 UTC

Exelixis Inc's shares are higher in after-market trading, reflecting notable strength despite no specific news to explain the price action.

19 ago 2026, 19:36 UTC

News

BMO Capital initiated coverage on Exelixis Inc with a Market Perform rating and a price target of $54. Shares are trading higher today.

18 ago 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

13 ago 2026, 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

12 ago 2026, 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11 ago 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10 ago 2026, 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

8 ago 2026, 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

7 ago 2026, 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

6 ago 2026, 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

5 ago 2026, 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

4 ago 2026, 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

3 ago 2026, 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

31 lug 2026, 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

30 lug 2026, 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

29 lug 2026, 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

28 lug 2026, 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

27 lug 2026, 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

24 lug 2026, 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

22 lug 2026, 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Confronto tra pari

Modifica del prezzo

Exelixis Inc Previsione

Obiettivo di Prezzo

By TipRanks

-3.99% in calo

Previsioni per 12 mesi

Media 51.92 USD  -3.99%

Alto 64 USD

Basso 41 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Exelixis Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

15 ratings

4

Acquista

10

Mantieni

1

Vendi

Sentiment

By Acuity

171 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
help-icon Live chat